Imidazoline receptor (IR) (IR)

Imidazoline receptors are a distinct class of non-adrenergic receptors that bind compounds containing an imidazoline or guanidinium moiety. They are classified into three main subtypes: I1, which is primarily involved in blood pressure regulation; I2, which is associated with monoamine oxidase and cell proliferation; and I3, which modulates insulin secretion. On endothelial cells, both I1 and I2 receptors are expressed and contribute to vascular homeostasis by promoting vasodilation and inhibiting the proliferation of vascular smooth muscle cells, which helps prevent vascular remodeling and atherosclerosis. The endogenous ligand agmatine is synthesized within the endothelium and acts as a natural agonist for these receptors. Therapeutic agents like moxonidine and rilmenidine are selective I1 agonists used to treat hypertension, offering a more favorable side-effect profile than older, non-selective agents like clonidine. Beyond cardiovascular regulation, imidazoline receptors are being investigated for their roles in metabolic syndrome, chronic pain, and neuroprotection.

Other names

Imidazoline binding siteI-receptorI1 receptorI2 receptorI3 receptorNischarinIRASImidazoline receptor antisera selectedNISCH

Activation of I1 receptors in the rostral ventrolateral medulla (RVLM) reduces sympathetic outflow to lower blood pressure, while activation of I1 and I2 receptors on endothelial cells and vascular smooth muscle promotes vasodilation and inhibits pathological cell proliferation.